Podcasts about innoviva

Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding of the industry's evolution and the pivotal roles he played at Theravance, Merck, and J&J. The episode delves into the significance of intracellular protein interactions and FogPharma's focus on developing helicon peptides to address this unmet need. Dr. Mammen's emphasis on a moonshot culture at FogPharma, coupled with his strategic approach to commercial success in biotech, makes this episode essential listening for executives in the biotech industry who are looking to stay ahead of future trends and gain insights into the innovative approaches shaping the industry's landscape. His profound knowledge and experience position him as a thought leader, offering invaluable perspectives on the challenges and opportunities in biotech, making this episode a compelling resource for industry executives seeking to implement strategies for commercial success in the biotech sector. Biography: Mathai Mammen is a world-renowned innovator in drug discovery, development, and team and company building. He brings significant global R&D and corporate leadership experience to his role as CEO, President and Chairman at FogPharma. Most recently, Mathai was a member of the executive committee at Johnson & Johnson, where he served as executive vice president of pharmaceuticals, R&D. During his tenure, he spearheaded a significant evolution of Janssen's R&D, one of the largest R&D organizations in the world. Mathai was a key leader in Johnson & Johnson's bold foray into COVID vaccines and he helped drive Janssen's substantial growth to become one of the top pharmaceutical companies globally. Under Mathai's leadership, Janssen R&D executed 40+ acquisitions and licenses and 350+ strategic partnerships and collaborations. A central pillar of his strategy was data science, which he used to couple recent revolutionary advances in data, compute and algorithmic approaches to every aspect of discovering and developing medicines. Mathai led his team to global approvals of eight new medicines, including Tremfya™, Darzalex Faspro™, Balversa™, Carvykti™, Rybrevant™, Ponvory™, Spravato™ and Tecvayli™, with many additional global approvals for expanded indications of marketed products. Prior to his role at Johnson & Johnson, Mathai served as senior vice president at Merck, where he was responsible for multiple research areas, including cardiovascular, metabolic and renal diseases, immunology, oncology and immuno-oncology. Before Merck, he led R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides. Under his leadership, Theravance advanced a robust pipeline of multiple development-stage compounds resulting in five approved pharmaceutical products, and separated into two companies: Theravance Biopharma, Inc. and Innoviva, Inc. In addition to his extensive corporate experience, Mathai currently serves on the board of directors of 10x Genomics, Inc. He has authored more than 150 peer-reviewed publications and patents. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

In der heutigen Folge „Alles auf Aktien“ berichten die Finanzjournalistinnen Anja Ettel und Jana Sepehr über den Montags-Blues im Dax, eine Breitseite für Siemens und große Hoffnungen durch Big Pharma. Außerdem geht es um Biontech, Nasdaq China Index, GSK, Daimler Truck, Covestro, Mercedes-Benz Group, Siemens, Uniper, Deutsche Bank, Sartorius Vz, Nordex, RWE, Klarna, Twitter, Netflix, Meta, Amazon, Sanofi, Novartis, Pfizer, Entavis, Innoviva, Merck und ishares MSCI World Healthcare Sector ESG ETF (WKN: A2PHCD). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Straight from Benzinga newsdesk, hosts Brent Slava and Steve Krause bring you the market news and stocks to watch.On Fridays Benzinga's resident Options Expert Ryan Faloona joins us to spice things up.Subscribe to our Stocks To Watch Newsletter here : https://go.benzinga.com/sales-page-187126583617110118712659DWAC - reminder: PHUN and CFVI have traded closely with DWAC. these 3 stocks can be considered "Trump plays." CFVI is spac for Rumble video platform (which Trump has used in the past) and PHUN previously had a deal where Trump's campaign was using the company's software service. something interesting to mention: SNAP hasn't been very sensitive to TWTR/Musk news.JPM - other notable earnings dates in July: MS Thursday, C, WFC Friday, GS, BAC next week Monday, IBM Monday, NFLX Tues next week, TSLA Wed, UAL Wed, SNAP Thurs, Jul. 21, AAPL will be the last week in Jul., probably the 26th or 27thBGNE - how does the FDA panel work? when will we hear results?Today's 5 Stock Ideas:Digital World Acquisition Corp. (DWAC) - A play on competition (or a lack of competition) in the social media space. Big news in the space over the weekend was that Elon Musk terminated his deal to buy Twitter (TWTR). Shares of Digital World, the special purpose acquisition corporation (SPAC) that will merge with Trump Media and its Truth Social social media platform, were up about 15% on the report.JP Morgan (JPM) - Will kick off the big bank earnings season on Thursday of this week. Investors can expect JP Morgan's results to be out before 7 a.m. EDT on Thursday.Roblox (RBLX) - A play on some positive analyst commentary on Friday of last week. Data-driven research firm, M Science, issued a note that suggested Roblox's could be seeing a strong rebound in year-over-year bookings, a key metric for the company's investors.Innoviva (INVA) - A play on consolidation in the pharma space. Innoviva announced it will buy La Jolla Pharma (LJPC) in about a $150 million deal, or about $6.23 per share.Beigene (BGNE) - A play on an upcoming FDA date. An FDA panel is scheduled to review Beigene's esophageal squamous cell carcinoma treatment candidate on Tuesday of this week.Hosts:Steve Krause Reach out to Steve at stevekrause@benzinga.comSr. Reporter Benzinga NewsdeskBrent Slava Reach out to Brent at brent@benzinga.comSr. Reporter, Head of Benzinga NewsdeskRyan Faloona Reach out to Ryan at ryanfaloona@benzinga.comDirector of Customer Successpro.benzinga.comFree 2-week trial, no credit card requiredUse coupon code YOUTUBE20 to get 20% offDisclaimer: All of the information, material, and/or content contained in this program is for informational purposes only. Investing in stocks, options, and futures is risky and not suitable for all investors. Please consult your own independent financial adviser before making any investment decisions.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

After a brief hiatus, my stock dissection series continues with Innoviva, a company with a portfolio of royalties and other healthcare assets. 

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

In the late nineties, a company named "Advanced Medicine" came together with the 4Cs of entrepreneurship in place: a concept, co-founders, capital, and some well-placed cold-calls. Mathai Mammen was one of those co-founders, still living in a dorm at the time. The company's investors evolved, it renamed itself, went public, and ultimately split into two independent companies: Innoviva (INVA) and Theravance Biopharma (TBPH). Today, Mathai is the SVP of R&D at Theravance Biopharma. Under his leadership, they have always done things a little differently. In the beginning they used their seed capital to build an in-house vivarium. They have discovered all of their development candidates - 31 and counting - internally or collaboratively. And after 3 approvals, they left their royalty stream to Innoviva and struck out on their own to focus on R&D - because "it's difficult to be innovative when you're in the shadows." Mathai has had a longstanding reputation as one of the good guys in the industry, but in recent years he has doubled down. After two extraordinary family tragedies, he calls out the importance of persistence, humility, and empathy above all - both in and outside of business.